Sanofi and GlaxoSmithKline’s next generation Covid-19 vaccine could be used as a booster, after new data suggested that it elicits a strong immune response against the Omicron variant.
The French healthcare company said the “next-generation” booster jab delivered a “strong immune response” against variants of Covid-19, including Omicron, after two trials. It was safe and well tolerated in the study of 247 people.
The vaccine makers said their jab increased antibodies to tackle the BA.1 Omicron strain by 40-fold in participants who had received two messengerRNA shots, the technology used in popular vaccines from Moderna and BioNTech/Pfizer.
您已阅读25%（648字），剩余75%（1904字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。